Main Menu


Professor Johann de Bono's group has led on the development of this PARP inhibitor, an oral and well tolerated anticancer drug that is now approved based on our work for the treatment of ovarian cancer.

Olaparib AZD2281 clinical trials

We have now presented data at a Plenary Presentation at the AACR Annual Meeting 2015 in Philadelphia that this drug has important antitumour activity in patients with advanced prostate cancer whose tumours have defects in their DNA repair machinery.